ReviewEuropean journal of clinical nutrition2019
Determinants of ectopic liver fat in metabolic disease.
Review in European journal of clinical nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolic aspects of surgical subcutaneous fat removal: An umbrella review and implications for future research.Biomolecules & biomedicine · 2023Pooled it
- Integration of 12-h time-restricted feeding with exercise training potentiates weight loss and attenuates MASLD in diet-induced obese mice.Scientific reports · 2026Article
- Adenylosuccinate Synthase 1 Deficiency Improves Energy Metabolism by Promoting Adipose Tissue Re-esterification via Glycerol Kinase Upregulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Body Mass Index Outperforms Triglyceride-Glucose Index in Predicting MAFLD in Type 2 Diabetes: A Cross-Sectional Mediation and Interaction Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Decoding survival in MASLD: the dominant role of metabolic factors.Diabetology & metabolic syndrome · 2025Article
- Dose-response relationship between the fatty liver index and asthma risk: NHANES 2001~2018.Endocrine journal · 2025Article
- Advances in body composition: a 100-year journey.International journal of obesity (2005) · 2025Review
- Estrogen regulation of the nucleus accumbens as a gateway to understanding menopause associated metabolic dysfunction.npj women's health · 2025Article
- Metabolic syndrome.Nature reviews. Disease primers · 2024Review
- Article
- Associations of Skeletal Muscle Mass, Muscle Fat Infiltration, Mitochondrial Energetics, and Cardiorespiratory Fitness With Liver Fat Among Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Adipose-targeted SWELL1 deletion exacerbates obesity- and age-related nonalcoholic fatty liver disease.JCI insight · 2023Article
- 4-PBA inhibits hypoxia-induced lipolysis in rat adipose tissue and lipid accumulation in the liver through regulating ER stress.Food science & nutrition · 2023Article
- Distinct impacts of fat and fructose on the liver, muscle, and adipose tissue metabolome: An integrated view.Frontiers in endocrinology · 2022Article
- ANGPTL8 promotes adipogenic differentiation of mesenchymal stem cells: potential role in ectopic lipid deposition.Frontiers in endocrinology · 2022Article
- Amelioration of obesity-related metabolic disorders via supplementation ofFrontiers in nutrition · 2022Article
- The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis.Journal of hepatology · 2021Article
- Metabolic-associated fatty liver disease and lipoprotein metabolism.Molecular metabolism · 2021Review
- Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects.International journal of general medicine · 2021Article
- Similar Metabolic Health in Overweight/Obese Individuals With Contrasting Metabolic Flexibility to an Oral Glucose Tolerance Test.Frontiers in nutrition · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Common obesity-associated hepatic steatosis (nonalcoholic fatty liver disease (NAFLD)) and insulin resistance are mainly caused by dysfunctional adipose tissue. This adipose tissue dysfunction leads to increased delivery of NEFA and glycerol to the liver that (i) drives hepatic gluconeogenesis and (ii) facilitates the accumulation of lipids and insulin signaling inhibiting lipid intermediates. Dysfunctional adipose tissue can be caused by impaired lipid storage (overflow hypothesis, characterized by large visceral adipocytes) or increased lipolysis (due to impaired postprandial suppression of lipolysis in inflamed, insulin-resistant adipocytes). In line with the adipose tissue expandability hypothesis the amount and distribution of adipose tissue correlate with its dysfunction and thus with liver fat. This relationship is however modified by endocrine effects on lipid storage and lipolysis as well as dietary effects on hepatic lipogenesis and lipid oxidation. The association between body composition characteristics like visceral obesity or fat cell size and ectopic liver fat is modified by these influences. Phenotyping obesity according to metabolic risk should integrate body composition characteristics, endocrine parameters and information on diet.
Indexed as
Identifiers
30323174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.